---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011145"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:51:33.085206+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech revenue up 42% to $65M in FY2023; net loss narrows to $4.4M

## Summary
- FY2023 net revenue of $65.0M, up 42% from $45.8M in FY2022.
- Q4 2023 record sales of $17.7M; net loss of $0.3M vs $4.2M loss in Q4 2022.
- FY2023 net loss of $4.4M, improved from $8.1M loss in FY2022.
- Adjusted EBITDA negative $0.3M for FY2023 vs negative $7.5M in prior year; Q4 breakeven.
- Launched ALLOCYTE Plus and BIASURGE; signed exclusive license with Tufts University for peptide tech.

## SEC filing metadata
- accession: 0001493152-24-011145
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/0001493152-24-011145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011145
- JSON: https://secwatch.observer/filing/0001493152-24-011145.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011145.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported the quarter and year ended December 31, 2023 results: revenue $17.7 million, net income net loss of $0.3 million.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $17.7 million
  - Net income: net loss of $0.3 million
  - Result: reported results
  source text: outcomes and reduce costs throughout the U.S.” Strategic and Operational Highlights in the Fourth Quarter 2023 ● In the fourth quarter 2023, the Company generated a record $17.7 million in sales, representing a ninth record revenue quarter for the Company. ● For the three months ended December 31, 2023, the Company had a net loss of $0.3 million, compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/0001493152-24-011145-index.htm
- Earnings Releases
  Sanara MedTech Inc. reported the year ended December 31, 2023 results: revenue $65.0 million, net income net loss of $4.4 million.
  - Period: the year ended December 31, 2023
  - Revenue: $65.0 million
  - Net income: net loss of $4.4 million
  - Result: reported results
  source text: For the year ended December 31, 2023, Sanara generated net revenues of $65.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315224011145/0001493152-24-011145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.